Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SINOPHARM GROUP CO. LTD.*

國藥控股股份有限公司

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 30 DECEMBER 2016

The board of directors (the "Board") of Sinopharm Group Co. Ltd. (the "Company") is pleased to announce that the extraordinary general meeting (the "EGM") was held at Meeting Room 1813, Sinopharm Plaza, No. 1001 Zhongshan West Road, Changning District, Shanghai, the People's Republic of China (the "PRC") at 9:00 a.m. on Friday, 30 December 2016. The resolution proposed at the EGM was duly passed by way of poll.

The poll results in respect of the resolution proposed at the EGM are as follows:

Special Resolution

Number of Valid Votes (%)

For

Against

1.

To consider and, if thought fit, to approve (i) the issue of the accounts receivable asset-backed securities in the PRC of no more than RMB8 billion in scale (the "Asset-backed Securities"); and (ii) the authorisation to the board of directors of the Company or the person(s) authorised by it deal with all specific matters pursuant to the proposal in respect of the issue of the Asset-backed Securities as set out in the notice of EGM of the Company dated 14 November 2016.

2,316,054,448

99.95%

1,074,481

0.05%

As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.

As at the date of the EGM, the total number of issued shares of the Company and the total number of shares entitling the holders to attend and vote for or against the resolution proposed at the EGM was

2,767,095,089 shares. There were no shares entitling the shareholders of the Company (the "Shareholders") to attend and shall abstain from voting in favour of any resolution proposed at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Hong Kong Listing Rules"), and no shares of holders that are required under the Hong Kong Listing Rules to abstain from voting. There were no parties had stated their intention in the circular of the Company dated 14 November 2016 to vote against the resolution proposed at the EGM or to abstain from voting.

Shareholders and authorized proxies holding an aggregate of 2,317,128,929 shares, representing 83.74% of the total issued share capital of the Company, were present at the EGM. The holding of the EGM was in compliance with the requirements of the Company Law of the PRC and the articles of association of the Company. The EGM was chaired by Mr. Wei Yulin, the Chairman of the Board.

In compliance with the requirements of the Hong Kong Listing Rules, Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as scrutineer for the vote-taking at the EGM.

By order of the Board of

Sinopharm Group Co. Ltd.

Wei Yulin

Chairman

Shanghai, the PRC 30 December 2016

As at the date of this announcement, the executive directors of the Company are Mr. Wei Yulin and Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong and Mr. Wu Yijian; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

Sinopharm Group Co. Ltd. published this content on 30 December 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 December 2016 04:27:06 UTC.

Original documenthttp://sinopharm.todayir.com/attachment/2016123012170100002695138_en.pdf

Public permalinkhttp://www.publicnow.com/view/A878DAA3D1FD39E1DC8EAAEDE986D36903A8F554